June 14, 2021
Article
The researchers analyzed patients with lung cancer before they underwent surgery and calculated their excess body weight using visceral fat index measured by CT scans.
June 09, 2021
Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.
June 08, 2021
Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.
While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.
June 06, 2021
Researchers estimate a 5-year overall survival rate of 42.9% for patients treated with durvalumab compared with 33.4% for those administered a placebo after chemoradiation therapy.
June 01, 2021
Lung cancer, the most common cancer type with the highest mortality, can largely be categorized by the genetic mutations that cause it.
This is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting.
May 25, 2021
The objective of the study was to determine whether atezolizumab could also be efficacious for patients with earlier-stage disease who may be at risk of disease recurrence following surgery
May 21, 2021
In a trial of amivantamab-vmjw, investigators found an overall response rate of 40% among patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations.
Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer
